大家好，这里是集才华与美貌与性感与骚气的大胸xie！欢迎大家来到每日22点更新的文献速递环节。今天是年7月28日星期二！
今天的文献速递内容主要有：
1
与单甲基auristatinE共价连接的抗LY6E的抗体偶联药物DLYEA治疗难治性实体瘤的Ⅰ期临床试验
2
支气管镜介入治疗原发性肺涎腺肿瘤的临床疗效及作用
3
ALK重排肺腺癌中抗PD1治疗的完全和长期反应
优秀的青年们，别忘了读文献哦~
阅读小提示：将DOI复制到scihub可以到查找全文~
1
APhaseIstudyofDLYEA,ananti-LY6EantibodycovalentlylinkedtomonomethylauristatinE,inpatientswithrefractorysolidtumors
与单甲基auristatinE共价连接的抗LY6E的抗体偶联药物DLYEA治疗难治性实体瘤的Ⅰ期临床试验
PURPOSE
DLYEAisanantibody-drugconjugateconsistingofananti-LY6EantibodycovalentlylinkedtothecytotoxicagentmonomethylauristatinE.Thisstudycharacterizedthesafety,pharmacokinetics,immunogenicity,potentialbiomarkers,andanti-tumoractivityofDLYEAinpatientswithmetastaticsolidtumors.
EXPERIMENTALDESIGN
ThiswasaphaseI,open-label,3+3dose-escalation,anddoseexpansionstudyofDLYEAadministeredintravenouslyevery21days(Q3W)inpatientswithlocallyadvancedormetastaticsolidmalignancies.
RESULTS
Sixty-eightpatientsreceivedDLYEA(median:4cycles;range:1-27).Nodoselimitingtoxicitieswereidentifiedduringdoseescalation(0.2-2.4mg/kg;n=20).There